Brace Yourselves for the Libertarian Tech Bro Takeover of the FDA

Ticker

Monika Bauerlein,
CEO

Dear Reader,

The next few months are make-or-break for Mother Jones’ fundraising, and we need more online readers to pitch in than have been of late. In "It's Not a Crisis. This Is the New Normal," we take a level-headed look at the brutal economics of journalism, why investigative reporting like you get from us matters, and why we're optimistic we can grow our base of support in a big way—starting with hitting a huge $300,000 goal in just three weeks. Please learn more and donate if you can right now.

The next few months are make-or-break for Mother Jones’ fundraising. We need to raise $300,000 quickly, and we need more online readers to pitch in than have been. Please learn more in "It's Not a Crisis. This Is the New Normal," where we go into the brutal economics of journalism, and what makes Mother Jones unique and worth supporting if you can right now.

<a href="http://www.istockphoto.com/photo/child-with-stomach-pain-gm468502327-34696976?st=_p_food%20poisoning">vitapix</a>/iStock

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

President-elect Donald Trump is taking his time choosing a nominee for secretary of the US Department of Agriculture—it’s the last open Cabinet post. But the USDA isn’t the only federal agency that lacks a proposed incoming leader just a week ahead of Inauguration Day. And while candidates for the USDA post have streamed thorough Trump Tower and Mar-a-Lago to plead their case, the Trump team has revealed little about whom it’s considering to head the Food and Drug Administration.

O’Neill declared that the FDA should stop requiring drug makers to prove their products actually work—”Let’s prove efficacy after they’ve been legalized,” he said.

Until Thursday. Stat News reports that two Silicon Valley titans, Jim O’Neill and Balaji Srinivasan, met with Trump on January 12 to “discuss running the agency.” Neither are medical doctors or scientists—the typical backgrounds for most previous FDA commissioners. Rather, they’re tech guru-investors who espouse virulently libertarian views, including disdain for the FDA’s role in regulating the pharmaceutical industry.

O’Neill is a managing director of Mithril Capital, an investment firm founded by Peter Thiel, himself a hyperlibertarian investor and an early supporter of Trump’s candidacy. In a 2014 speech before a biotechnology group, O’Neill declared that the FDA should stop requiring drug makers to prove their products actually work—”Let’s prove efficacy after they’ve been legalized,” he said.

Srinivasan, co-founder of the bitcoin startup 21.co and a partner at the venture capital firm at Andreessen Horowitz, has opined that information technology makes the FDA role in drug regulation obsolete:

New tech also allows far better regulation than FDA. Scan a drug barcode, get 1000 worldwide MD opinions and 1 million patient self reports.

— Balaji S. Srinivasan (@balajis) March 22, 2016

Srinivasan, too, is associated with Thiel, who is an investor in Srinivasan’s bitcoin firm.

Neither Srinivasan nor O’Neill has said much publicly about the FDA’s other policy portfolio: overseeing food safety, including recently enacted rules designed to push the meat industry to rely less on antibiotics necessary for human medicine.

Trump himself has been opaque on the question of food safety regulations—though back in September, his campaign website did post, and quickly remove, a “fact sheet” denouncing the “FDA food police.”